{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:26:10Z","timestamp":1761128770874},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,6,6]],"date-time":"2009-06-06T00:00:00Z","timestamp":1244246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s10096-009-0764-y","type":"journal-article","created":{"date-parts":[[2009,6,6]],"date-time":"2009-06-06T00:34:59Z","timestamp":1244248499000},"page":"1209-1215","source":"Crossref","is-referenced-by-count":6,"title":["In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies"],"prefix":"10.1007","volume":"28","author":[{"name":"Coll\u00e8ge de Bact\u00e9riologie Virologie Hygi\u00e8ne Study Group (ColBVH)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Gallon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Guillet-Caruba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Doucet-Populaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-W.","family":"Decousser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,6]]},"reference":[{"key":"764_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.diagmicrobio.2006.05.009","volume":"57","author":"GJ Moet","year":"2007","unstructured":"Moet GJ, Jones RN, Biedenbach DJ et al (2007) Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998\u20132004). Diagn Microbiol Infect Dis 57:7\u201313. doi: 10.1016\/j.diagmicrobio.2006.05.009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"764_CR2","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/jac\/dkg201","volume":"51","author":"JW Decousser","year":"2003","unstructured":"Decousser JW, Pina P, Picot F et al (2003) Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J Antimicrob Chemother 51:1213\u20131222. doi: 10.1093\/jac\/dkg201","journal-title":"J Antimicrob Chemother"},{"key":"764_CR3","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1128\/AAC.48.9.3636-3639.2004","volume":"48","author":"JW Decousser","year":"2004","unstructured":"Decousser JW, Pina P, Viguier F et al (2004) Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002. Antimicrob Agents Chemother 48:3636\u20133639. doi: 10.1128\/AAC.48.9.3636-3639.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1128\/AAC.00906-07","volume":"52","author":"M Galas","year":"2008","unstructured":"Galas M, Decousser JW, Breton N et al (2008) Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae in France. Antimicrob Agents Chemother 52:786\u2013789. doi: 10.1128\/AAC.00906-07","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR5","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical breakpoints. Available online at: http:\/\/www.srga.org\/eucastwt\/MICTAB\/index.html"},{"key":"764_CR6","unstructured":"French Society of Microbiology (CASFM) Guidelines of the Antimicrobial Committee of the French Society of Microbiology. Available online at: http:\/\/www.sfm.asso.fr\/nouv\/general.php?pa=2"},{"key":"764_CR7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1086\/313461","volume":"29","author":"G Lina","year":"1999","unstructured":"Lina G, Pi\u00e9mont Y, Godail-Gamot F et al (1999) Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29:1128\u20131132. doi: 10.1086\/313461","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"764_CR8","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1086\/519470","volume":"45","author":"MH Kollef","year":"2007","unstructured":"Kollef MH (2007) Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 45(Suppl 3):S191\u2013S195. doi: 10.1086\/519470","journal-title":"Clin Infect Dis"},{"key":"764_CR9","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Graves J, Evans A et al (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315\u20133320. doi: 10.1128\/AAC.00113-08","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:1330\u20131336","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR11","unstructured":"European Antimicrobial Resistance Surveillance System (EARSS) Home page at: http:\/\/www.rivm.nl\/earss"},{"key":"764_CR12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3201\/eid0908.030089","volume":"9","author":"F Vandenesch","year":"2003","unstructured":"Vandenesch F, Naimi T, Enright MC et al (2003) Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 9:978\u2013984","journal-title":"Emerg Infect Dis"},{"key":"764_CR13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcp070747","volume":"357","author":"RS Daum","year":"2007","unstructured":"Daum RS (2007) Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 357:380\u2013390. doi: 10.1056\/NEJMcp070747","journal-title":"N Engl J Med"},{"key":"764_CR14","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1128\/JCM.00076-06","volume":"44","author":"JH Jorgensen","year":"2006","unstructured":"Jorgensen JH, Crawford SA (2006) Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J Clin Microbiol 44:2126\u20132129. doi: 10.1128\/JCM.00076-06","journal-title":"J Clin Microbiol"},{"key":"764_CR15","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1128\/JCM.00665-06","volume":"44","author":"LA Jevitt","year":"2006","unstructured":"Jevitt LA, Thorne GM, Traczewski MM et al (2006) Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J Clin Microbiol 44:3098\u20133104. doi: 10.1128\/JCM.00665-06","journal-title":"J Clin Microbiol"},{"key":"764_CR16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkh143","volume":"53","author":"JM Streit","year":"2004","unstructured":"Streit JM, Jones RN, Sader HS (2004) Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 53:669\u2013674. doi: 10.1093\/jac\/dkh143","journal-title":"J Antimicrob Chemother"},{"key":"764_CR17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1469-0691.2006.01550.x","volume":"12","author":"HS Sader","year":"2006","unstructured":"Sader HS, Streit JM, Fritsche TR et al (2006) Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002\u20132004). Clin Microbiol Infect 12:844\u2013852. doi: 10.1111\/j.1469-0691.2006.01550.x","journal-title":"Clin Microbiol Infect"},{"key":"764_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-7-29","volume":"7","author":"HS Sader","year":"2007","unstructured":"Sader HS, Watters AA, Fritsche TR et al (2007) Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 7:29. doi: 10.1186\/1471-2334-7-29","journal-title":"BMC Infect Dis"},{"key":"764_CR19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkg130","volume":"51","author":"IA Critchley","year":"2003","unstructured":"Critchley IA, Draghi DC, Sahm DF et al (2003) Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000\u20132001. J Antimicrob Chemother 51:639\u2013649. doi: 10.1093\/jac\/dkg130","journal-title":"J Antimicrob Chemother"},{"key":"764_CR20","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.00257-08","volume":"52","author":"SN Leonard","year":"2008","unstructured":"Leonard SN, Cheung CM, Rybak MJ (2008) Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52:2974\u20132976. doi: 10.1128\/AAC.00257-08","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/AAC.48.3.1007-1011.2004","volume":"48","author":"AC Fluit","year":"2004","unstructured":"Fluit AC, Schmitz FJ, Verhoef J et al (2004) In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 48:1007\u20131011. doi: 10.1128\/AAC.48.3.1007-1011.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","volume":"355","author":"GJ Moran","year":"2006","unstructured":"Moran GJ, Krishnadasan A, Gorwitz RJ et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666\u2013674. doi: 10.1056\/NEJMoa055356","journal-title":"N Engl J Med"},{"key":"764_CR23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMe068152","volume":"355","author":"ML Grayson","year":"2007","unstructured":"Grayson ML (2007) The treatment triangle for staphylococcal infections. N Engl J Med 355:724\u2013727. doi: 10.1056\/NEJMe068152","journal-title":"N Engl J Med"},{"key":"764_CR24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","volume":"44","author":"FC Tenover","year":"2007","unstructured":"Tenover FC, Moellering RC (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208\u20131215. doi: 10.1086\/513203","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"764_CR25","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1086\/533595","volume":"46","author":"SE Cosgrove","year":"2008","unstructured":"Cosgrove SE, Fowler VG Jr (2008) Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46(Suppl 5):S386\u2013S393. doi: 10.1086\/533595","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"764_CR26","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/519471","volume":"45","author":"ST Micek","year":"2007","unstructured":"Micek ST (2007) Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 45(Suppl 3):S184\u2013S190. doi: 10.1086\/519471","journal-title":"Clin Infect Dis"},{"key":"764_CR27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s10096-003-0959-6","volume":"22","author":"EH Ben Mansour","year":"2003","unstructured":"Ben Mansour EH, Jacob E, Monchi M et al (2003) Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 22:372\u2013373. doi: 10.1007\/s10096-003-0959-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 2","key":"764_CR28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1469-0691.2008.01924.x","volume":"14","author":"CK Naber","year":"2008","unstructured":"Naber CK (2008) Future strategies for treating Staphylococcus aureus bloodstream infections. Clin Microbiol Infect 14(Suppl 2):26\u201334","journal-title":"Clin Microbiol Infect"},{"key":"764_CR29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/520655","volume":"45","author":"HW Boucher","year":"2007","unstructured":"Boucher HW, Sakoulas G (2007) Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45:601\u2013608. doi: 10.1086\/520655","journal-title":"Clin Infect Dis"},{"key":"764_CR30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/AAC.34.6.1227","volume":"34","author":"PM Small","year":"1990","unstructured":"Small PM, Chambers HF (1990) Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34:1227\u20131231","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2007.06.001","volume":"59","author":"RN Jones","year":"2007","unstructured":"Jones RN, Fritsche TR, Sader HS et al (2007) Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 59:199\u2013209. doi: 10.1016\/j.diagmicrobio.2007.06.001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"764_CR32","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","volume":"49","author":"J Weigelt","year":"2005","unstructured":"Weigelt J, Itani K, Stevens D et al (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49:2260\u20132266. doi: 10.1128\/AAC.49.6.2260-2266.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR33","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","volume":"34","author":"DL Stevens","year":"2002","unstructured":"Stevens DL, Herr D, Lampiris H et al (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481\u20131490. doi: 10.1086\/340353","journal-title":"Clin Infect Dis"},{"key":"764_CR34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","volume":"36","author":"MC Birmingham","year":"2003","unstructured":"Birmingham MC, Rayner CR, Meagher AK et al (2003) Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36:159\u2013168. doi: 10.1086\/345744","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-009-0764-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-009-0764-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-009-0764-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:34:14Z","timestamp":1559122454000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-009-0764-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,6]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s10096-009-0764-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2009,6,6]]}}}